

30. (currently amended) A method for diagnosing or treating a Dengue virus-related condition in a cell, tissue, organ, patient, animal or population of subjects comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody ~~having either (i) all of the heavy chain CDR amino acid sequences of SEQ ID NO: 3; or (ii) all of the light chain CDR amino acid sequences of SEQ ID NO: 4~~ of claim 20, with, or to, said cell, tissue, organ, patient or animal.

49. (currently amended) A method for diagnosing or treating a Dengue virus related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody ~~having at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS: 3 or 4~~ of claim 1, with, or to, said cell, tissue, organ, patient or animal.

68. (currently amended) A method for diagnosing or treating a Dengue virus related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody that binds to the same region of a Dengue virus protein as ~~an antibody comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS: 3 or 4~~ the antibody of claim 1, with, or to, said cell, tissue, organ, patient or animal.

77. (currently amended) At least one isolated mammalian anti-Dengue virus antibody, comprising at least one human CDR, wherein said antibody specifically binds at least one epitope comprising at least 1-3 amino acids, to the entire amino acid sequence of a Dengue virus NS protein.

87. (currently amended) A method for diagnosing or treating a Dengue virus related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody ~~having at least one human CDR, wherein said antibody specifically binds at least one epitope comprising two or more amino acids of a Dengue virus NS1 protein of claim 77,~~ with, or to, said cell, tissue, organ, patient or animal.

91. (currently amended) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody or a nucleic acid molecule encoding said antibody, having at least one human CDR, wherein said antibody specifically binds at least one epitope comprising at least 1-3 amino acids, to the entire amino acid sequence of ~~SEQ ID NOS: 3 and 4~~ a Dengue virus NS protein, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, ~~or~~ and transdermal.